These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9185746)

  • 21. Lidocaine elimination in patients with liver cirrhosis.
    Wójcicki J; Kozłowski K; Droździk M; Wójcicki M
    Acta Pol Pharm; 2002; 59(4):321-4. PubMed ID: 12403308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of lidocaine metabolism to test liver function during the long-term follow-up of liver transplant recipients.
    Conti F; Dousset B; Cherruau B; Guérin C; Soubrane O; Houssin D; Calmus Y
    Clin Transplant; 2004 Jun; 18(3):235-41. PubMed ID: 15142042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Liver function test to predict hepatic failure after liver resection--expensive and without clinical relevance?].
    Kanzler S; Teufel A; Galle PR
    Zentralbl Chir; 2007 Aug; 132(4):267-73. PubMed ID: 17724626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic lidocaine metabolism and liver histology.
    Fabbri A; Bianchi GP; Marchesini G
    Hepatology; 1995 Jun; 21(6):1761-2. PubMed ID: 7768525
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation].
    Reichel C; Wienkoop G; Nacke A; Spengler U
    Dtsch Med Wochenschr; 1995 Feb; 120(6):179-83. PubMed ID: 7851289
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dynamic liver function study using the lidocaine test].
    Sídlová K; Průsa R
    Cas Lek Cesk; 2000 Sep; 139(19):604-5. PubMed ID: 11192753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass.
    Autschbach R; Falk V; Lange H; Oellerich M; Walther T; Mohr FW; Dalichau H
    Thorac Cardiovasc Surg; 1996 Apr; 44(2):76-80. PubMed ID: 8782332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The monoethylglycinexylidide test for grading of liver cirrhosis.
    Fabris L; Jemmolo RM; Toffolo G; Paleari D; Viaggi S; Rigon M; Casagrande F; Lirussi F; Strazzabosco M; Cobelli C; Okolicsanyi L
    Aliment Pharmacol Ther; 1999 Jan; 13(1):67-75. PubMed ID: 9892881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
    Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
    Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests.
    Meyer-Wyss B; Renner E; Luo H; Scholer A
    J Hepatol; 1993 Aug; 19(1):133-9. PubMed ID: 8301033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis.
    Arrigoni A; Gindro T; Aimo G; Cappello N; Meloni A; Benedetti P; Molino GP; Verme G; Rizzetto M
    Hepatology; 1994 Aug; 20(2):383-7. PubMed ID: 8045499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
    Shiffman ML; Luketic VA; Sanyal AJ; Thompson EB
    Ther Drug Monit; 1996 Aug; 18(4):372-7. PubMed ID: 8857553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lidocaine elimination and monoethylglycinexylidide formation in the dehydrated camel.
    Ben-Zvi Z; Goldin G; Van Creveld C; Yagil R
    J Vet Pharmacol Ther; 1995 Dec; 18(6):442-5. PubMed ID: 8789697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of one-year pretransplant survival in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Binder L; Pichlmayr R
    Hepatology; 1991 Dec; 14(6):1029-34. PubMed ID: 1959850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient.
    Potter JM; Hickman PE; Lynch SV; Henderson A; Wright M; Balderson G; Strong RW
    Transplantation; 1993 Dec; 56(6):1385-8. PubMed ID: 8279008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoethylglycinexylidide (MEGX) test in patients with different liver diseases.
    Gruttadauria S; Marino G; Russello M; Gentile A; Denaro Papa F; Gruttadauria G
    Ann Ital Chir; 1998; 69(2):211-4. PubMed ID: 9718790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hypoxia on the hepatic metabolism of lidocaine in the isolated perfused pig liver.
    Mets B; Hickman R; Allin R; Van Dyk J; Lotz Z
    Hepatology; 1993 Apr; 17(4):668-76. PubMed ID: 8477972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis.
    Botta F; Giannini E; Fasoli A; Romagnoli P; Risso D; Testa R
    Ther Drug Monit; 2000 Aug; 22(4):371-4. PubMed ID: 10942173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.